therapeutics

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies…

4 weeks ago

Ernexa Therapeutics to Present at Oxford Globals Cell 2025

Sanjeev Luther, President and CEO to give an oral presentation and participate in a moderated panel discussion November 11, 2025…

4 weeks ago

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism…

4 weeks ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

November 08, 2025 17:13 ET  | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…

4 weeks ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the…

1 month ago

Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa

DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a…

1 month ago

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its…

1 month ago

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

November 03, 2025 16:45 ET  | Source: Fulcrum Therapeutics, Inc. ― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell…

1 month ago

Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel)

CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene…

1 month ago

EmblemHealth and Prime Therapeutics Pioneer New Pharmacy Benefit Collaboration

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- EmblemHealth, one of the largest not-for-profit health insurers in the nation, today…

1 month ago